The Experts below are selected from a list of 7155 Experts worldwide ranked by ideXlab platform

Wei Lu - One of the best experts on this subject based on the ideXlab platform.

  • effect of inhibition of spinal cord Glutamate transporters on inflammatory pain induced by formalin and complete freund s adjuvant
    Anesthesiology, 2011
    Co-Authors: Myron Yaster, Xiaowei Guan, Jeffrey D Rothstein, Ronald S Petralia, Wei Lu
    Abstract:

    Background—Spinal cord Glutamate transporters clear synaptically released Glutamate and maintain normal sensory transmission. However, their ultrastructural localization is unknown. Moreover, whether and how they participate in inflammatory pain has not been carefully studied. Methods—Immunogold labeling with electron microscopy was carried out to characterize synaptic and non-synaptic localization of Glutamate transporters in the superficial dorsal horn. Their expression and uptake activity after formalin- and complete Freund’s adjuvant (CFA)induced inflammation were evaluated by Western blot and Glutamate uptake assays. Effects of intrathecal Glutamate transporter activator [(R)-(−)-5-methyl-1-nicotinoyl-2-pyrazoline], inhibitors [DL-threo-β-benzyloxyaspartate (TBOA), dihydrokainate, and DL-threo-beta-hydroxyaspartate], or TBOA plus a group III metabotropic Glutamate Receptor Antagonist [(RS)-α-methylserine-Ophosphate] on formalin- and CFA-induced inflammatory pain were examined.

  • Effect of inhibition of spinal cord Glutamate transporters on inflammatory pain induced by formalin and complete Freund’s adjuvant
    Anesthesiology, 2011
    Co-Authors: Myron Yaster, Xiaowei Guan, Jeffrey D Rothstein, Ronald S Petralia, Wei Lu
    Abstract:

    Background—Spinal cord Glutamate transporters clear synaptically released Glutamate and maintain normal sensory transmission. However, their ultrastructural localization is unknown. Moreover, whether and how they participate in inflammatory pain has not been carefully studied. Methods—Immunogold labeling with electron microscopy was carried out to characterize synaptic and non-synaptic localization of Glutamate transporters in the superficial dorsal horn. Their expression and uptake activity after formalin- and complete Freund’s adjuvant (CFA)induced inflammation were evaluated by Western blot and Glutamate uptake assays. Effects of intrathecal Glutamate transporter activator [(R)-(−)-5-methyl-1-nicotinoyl-2-pyrazoline], inhibitors [DL-threo-β-benzyloxyaspartate (TBOA), dihydrokainate, and DL-threo-beta-hydroxyaspartate], or TBOA plus a group III metabotropic Glutamate Receptor Antagonist [(RS)-α-methylserine-Ophosphate] on formalin- and CFA-induced inflammatory pain were examined.

Ian S. Blagbrough - One of the best experts on this subject based on the ideXlab platform.

Kiyofumi Gyo - One of the best experts on this subject based on the ideXlab platform.

  • ampa kainate type Glutamate Receptor Antagonist reduces progressive inner hair cell loss after transient cochlear ischemia
    Brain Research, 2003
    Co-Authors: Nobuhiro Hakuba, Atsushi Matsubara, Jun Hyodo, Masafumi Taniguchi, Toshiki Maetani, Yoshitaka Shimizu, Yuko Tsujiuchi, Masachika Shudou, Kiyofumi Gyo
    Abstract:

    We investigated the effect of Glutamate Receptor Antagonists on progressive inner hair cell (IHC) loss following transient cochlear ischemia in gerbils. Transient cochlear ischemia was induced by 15-min bilateral vertebral artery occlusion. An alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA)/kainate-type Glutamate Receptor Antagonist, 6-7-dinitroquinoxaline-2,3-dione (DNQX), or an N-methyl-D-aspartate (NMDA)-type Receptor Antagonist, MK-801, was administered 10 min before the ischemic insult. Hearing was assessed by sequentially recording compound action potentials (CAPs) before, during, and after the ischemia. The degree of hair cell loss in the organ of Corti was evaluated in specimens stained with rhodamine-phalloidin and Hoechst 33342. On the seventh day after ischemia, the increases in the CAP threshold and the progressive IHC loss were significantly reduced in cochleae treated with DNQX, while MK-801 was ineffective. These results suggest that the AMPA Receptor plays a critical role in the development of the progressive IHC loss induced by ischemia/reperfusion injury in the cochlea.

  • AMPA/kainate-type Glutamate Receptor Antagonist reduces progressive inner hair cell loss after transient cochlear ischemia
    Brain Research, 2003
    Co-Authors: Nobuhiro Hakuba, Atsushi Matsubara, Jun Hyodo, Masafumi Taniguchi, Toshiki Maetani, Yoshitaka Shimizu, Yuko Tsujiuchi, Masachika Shudou, Kiyofumi Gyo
    Abstract:

    We investigated the effect of Glutamate Receptor Antagonists on progressive inner hair cell (IHC) loss following transient cochlear ischemia in gerbils. Transient cochlear ischemia was induced by 15-min bilateral vertebral artery occlusion. An alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA)/kainate-type Glutamate Receptor Antagonist, 6-7-dinitroquinoxaline-2,3-dione (DNQX), or an N-methyl-D-aspartate (NMDA)-type Receptor Antagonist, MK-801, was administered 10 min before the ischemic insult. Hearing was assessed by sequentially recording compound action potentials (CAPs) before, during, and after the ischemia. The degree of hair cell loss in the organ of Corti was evaluated in specimens stained with rhodamine-phalloidin and Hoechst 33342. On the seventh day after ischemia, the increases in the CAP threshold and the progressive IHC loss were significantly reduced in cochleae treated with DNQX, while MK-801 was ineffective. These results suggest that the AMPA Receptor plays a critical role in the development of the progressive IHC loss induced by ischemia/reperfusion injury in the cochlea.

Eduardo Moya - One of the best experts on this subject based on the ideXlab platform.

Ronald S Petralia - One of the best experts on this subject based on the ideXlab platform.

  • effect of inhibition of spinal cord Glutamate transporters on inflammatory pain induced by formalin and complete freund s adjuvant
    Anesthesiology, 2011
    Co-Authors: Myron Yaster, Xiaowei Guan, Jeffrey D Rothstein, Ronald S Petralia, Wei Lu
    Abstract:

    Background—Spinal cord Glutamate transporters clear synaptically released Glutamate and maintain normal sensory transmission. However, their ultrastructural localization is unknown. Moreover, whether and how they participate in inflammatory pain has not been carefully studied. Methods—Immunogold labeling with electron microscopy was carried out to characterize synaptic and non-synaptic localization of Glutamate transporters in the superficial dorsal horn. Their expression and uptake activity after formalin- and complete Freund’s adjuvant (CFA)induced inflammation were evaluated by Western blot and Glutamate uptake assays. Effects of intrathecal Glutamate transporter activator [(R)-(−)-5-methyl-1-nicotinoyl-2-pyrazoline], inhibitors [DL-threo-β-benzyloxyaspartate (TBOA), dihydrokainate, and DL-threo-beta-hydroxyaspartate], or TBOA plus a group III metabotropic Glutamate Receptor Antagonist [(RS)-α-methylserine-Ophosphate] on formalin- and CFA-induced inflammatory pain were examined.

  • Effect of inhibition of spinal cord Glutamate transporters on inflammatory pain induced by formalin and complete Freund’s adjuvant
    Anesthesiology, 2011
    Co-Authors: Myron Yaster, Xiaowei Guan, Jeffrey D Rothstein, Ronald S Petralia, Wei Lu
    Abstract:

    Background—Spinal cord Glutamate transporters clear synaptically released Glutamate and maintain normal sensory transmission. However, their ultrastructural localization is unknown. Moreover, whether and how they participate in inflammatory pain has not been carefully studied. Methods—Immunogold labeling with electron microscopy was carried out to characterize synaptic and non-synaptic localization of Glutamate transporters in the superficial dorsal horn. Their expression and uptake activity after formalin- and complete Freund’s adjuvant (CFA)induced inflammation were evaluated by Western blot and Glutamate uptake assays. Effects of intrathecal Glutamate transporter activator [(R)-(−)-5-methyl-1-nicotinoyl-2-pyrazoline], inhibitors [DL-threo-β-benzyloxyaspartate (TBOA), dihydrokainate, and DL-threo-beta-hydroxyaspartate], or TBOA plus a group III metabotropic Glutamate Receptor Antagonist [(RS)-α-methylserine-Ophosphate] on formalin- and CFA-induced inflammatory pain were examined.